Please assess the completion status of the following clinical trial:

Trial Title: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion critieria:~* Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that carries an ALK rearrangement, as per the FDA-approved FISH assay (Abbott Molecular Inc.).~* Age 18 years or older at the time of informed consent.~* Patients must have NSCLC that has progressed during therapy with crizotinib or within 30 days of the last dose~* Patients must have received 1-3 lines of cytotoxic chemotherapy (of which 1 must have been a platinum doublet) to treat their locally advanced or metastatic NSCLC~* Patients must have a tumor tissue sample available, collected either at the time of diagnosis of NSCLC or any time since.~* Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.~Exclusion criteria:~* Patients with known hypersensitivity to any of the excipients of LDK378.~* Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.~* History of carcinomatous meningitis.~* Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.~* Clinically significant, uncontrolled heart disease~* Systemic anti-cancer therapy given after the last dose of crizotinib and prior to starting study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDK378 (Type: EXPERIMENTAL): Patients treated with ceritinib/LDK378 750 mg once-daily, fasted

Based on this trial design, predict the completion outcome and termination type (if applicable).